Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Posoleucel - Kalaris Therapeutics

Next Previous
Drug Profile

Posoleucel - Kalaris Therapeutics

Alternative Names: ALVR-105; Multivirus-specific T cell therapy - Kalaris Therapeutics; Viralym-M

Latest Information Update: 09 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Baylor College of Medicine
  • Developer Baylor College of Medicine; Kalaris Therapeutics
  • Class Antivirals; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adenovirus infections; Polyomavirus infections; Epstein-Barr virus infections; Cystitis; Cytomegalovirus infections; Human herpesvirus 6 infections
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Adenovirus infections; Cystitis; Cytomegalovirus infections; Epstein-Barr virus infections; Human herpesvirus 6 infections; Polyomavirus infections

Most Recent Events

  • 09 Feb 2026 Discontinued - Phase-II for Adenovirus infections in USA (IV)
  • 09 Feb 2026 Discontinued - Phase-II for Cytomegalovirus infections in USA (IV)
  • 09 Feb 2026 Discontinued - Phase-II for Epstein-Barr virus infections in USA (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top